文献速递头颈部肿瘤放疗

局部晚期头颈鳞癌选择性淋巴结减量放疗的单臂2期试验

Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-12-28

该单臂2期试验评估了局部晚期头颈鳞癌采用选择性颈淋巴结低剂量(36 Gy)同步顺铂放化疗的方案,主要终点为选择性淋巴结失败。54例患者中无一例发生选择性淋巴结失败,3年生存率91%,常见3级毒性为吞咽困难(79%),患者报告结局在6个月时恢复至基线。

要点

  • 选择性颈淋巴结放疗剂量降至36 Gy后,54例中无一例出现选择性淋巴结失败。
  • 全组3年生存率91%,HPV阳性者96%,HPV阴性者85%。
  • 常见3级毒性包括吞咽困难79%、黏膜炎/口腔炎41%、恶心20%。

核心结论

  • 该放化疗方案对晚期头颈鳞癌显示出降低选择性颈淋巴结剂量的可行性,需未来临床试验进一步研究。

研究设计与样本

  • 单臂2期试验纳入54例局部晚期口腔、口咽、喉或下咽鳞癌患者。
  • 治疗方案为7周疗程:每周顺铂35 mg/m2同步序贯推量调强放疗,高危和低危计划靶区先给36 Gy,后高危计划靶区推量至70 Gy。
  • 主要终点为选择性淋巴结失败,次要终点包括生存、毒性、喂养管持续时间和生活质量。

主要发现

  • 中位随访36个月(范围12-66个月),无患者发生选择性淋巴结失败。
  • 全组3年生存率91%(95%CI 0.79-0.96),HPV阴性组85%(95%CI 0.61-0.95),HPV阳性组96%(95%CI 0.77-0.99)。
  • 常见3级毒性为吞咽困难(79%)、黏膜炎和/或口腔炎(41%)、恶心(20%)、口干(13%)、呕吐(11%)、中性粒细胞减少(10%)。
  • 中位喂养管持续时间为142天。
  • FACT-HN评分在3、6、12个月时均高于治疗结束时(P < .0001),总FACT-HN评分在6个月时恢复至治疗前基线;QOL-RTI总评分从治疗前至治疗结束及12个月均较低(P = .0001)。

关键数值与推荐

  • 选择性颈淋巴结放疗剂量为36 Gy,高危计划靶区推量至70 Gy,同步每周顺铂35 mg/m2。

临床怎么用

  • 对于局部晚期头颈鳞癌,可考虑在临床试验条件下探索选择性颈淋巴结低剂量放疗。
  • 该方案下吞咽困难等3级毒性常见,需关注营养支持和喂养管管理。

局限性

  • 单臂设计,样本量54例,随访时间有限,结论需随机试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate a novel chemoradiation therapy (CRT) regimen for patients with squamous cell carcinoma of the head and neck (SCCHN) incorporating a lower intensity modulated radiation therapy dose to electively treated neck lymph nodes than is currently standard. METHODS AND MATERIALS: Eligible patients had locally advanced SCCHN of the oral cavity, oropharynx, larynx, or hypopharynx. The 7-week CRT course consisted of weekly cisplatin at 35 mg/m2 concurrently with sequential-boost intensity modulated radiation therapy: 36 Gy to high- and low-risk planning target volumes followed by a sequential boost to the high-risk planning target volume to 70 Gy. The primary endpoint was elective nodal failure. Secondary endpoints were survival, toxicity, feeding tube duration, and quality of life evaluated by the FACT-HN and QOL-RTI surveys. RESULTS: Between 2011 and 2014, 54 patients were enrolled, 31 (57%) of whom had human papillomavirus (HPV)-positive disease. Of the patients, 35 (65%) had stage IVa disease. The median follow-up period for survivors was 36 months (range, 12-66 months). Elective nodal failure did not develop in any patient. The actuarial 3-year survival rate for the entire cohort was 91% (95% confidence interval [CI] 0.79-0.96); for the HPV-negative group, 85% (95% CI 0.61-0.95); and for the HPV-positive group, 96% (95% CI 0.77-0.99). Common grade 3 toxicities were dysphagia (79%), mucositis and/or stomatitis (41%), nausea (20%), xerostomia (13%), vomiting (11%), and neutropenia (10%). The median feeding tube duration was 142 days. Patient FACT-HN scores were higher at 3, 6, and 12 months versus at the end of treatment (P < .0001). Total FACT-HN scores returned to pretreatment baseline by 6 months. Overall QOL-RTI scores were lower from pretreatment to the end of treatment through 12 months (P = .0001). CONCLUSIONS: This CRT regimen for patients with advanced SCCHN demonstrated the potential feasibility of reducing the elective dose to the neck, a topic that requires additional study in future clinical trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Maguire PD, Neal CR, Hardy SM, et al. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2017. PMID: 29452770. doi:10.1016/j.ijrobp.2017.12.277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。